Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation
Jianwen Wei, … , William S. Blaner, Gerard Karsenty
Jianwen Wei, … , William S. Blaner, Gerard Karsenty
Published March 18, 2014
Citation Information: J Clin Invest. 2014;124(4):1781-1793. https://doi.org/10.1172/JCI72323.
View: Text | PDF
Research Article Article has an altmetric score of 29

Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation

  • Text
  • PDF
Abstract

Insulin signaling in osteoblasts has been shown recently to contribute to whole-body glucose homeostasis in animals fed a normal diet; however, it is unknown whether bone contributes to the insulin resistance that develops in animals challenged by a high-fat diet (HFD). Here, we evaluated the consequences of osteoblast-specific overexpression of or loss of insulin receptor in HFD-fed mice. We determined that the severity of glucose intolerance and insulin resistance that mice develop when fed a HFD is in part a consequence of osteoblast-dependent insulin resistance. Insulin resistance in osteoblasts led to a decrease in circulating levels of the active form of osteocalcin, thereby decreasing insulin sensitivity in skeletal muscle. Insulin resistance developed in osteoblasts as the result of increased levels of free saturated fatty acids, which promote insulin receptor ubiquitination and subsequent degradation. Together, these results underscore the involvement of bone, among other tissues, in the disruption of whole-body glucose homeostasis resulting from a HFD and the involvement of insulin and osteocalcin cross-talk in glucose intolerance. Furthermore, our data indicate that insulin resistance develops in bone as the result of lipotoxicity-associated loss of insulin receptors.

Authors

Jianwen Wei, Mathieu Ferron, Christopher J. Clarke, Yusuf A. Hannun, Hongfeng Jiang, William S. Blaner, Gerard Karsenty

×

Figure 5

Insulin resistance in bone affects whole-body glucose homeostasis in mice fed a HFD by decreasing osteocalcin activity.

Options: View larger image (or click on image) Download as PowerPoint
Insulin resistance in bone affects whole-body glucose homeostasis in mic...
(A) Serum osteocalcin levels in WT mice fed a normal diet or a HFD (n = 8). (B) Serum osteocalcin levels in Insrfl/+ and Col1a1-Insr+/– mice fed a normal diet or a HFD (n = 8). (C) Serum osteocalcin levels in WT and Col1a1-INSRTg mice fed a normal diet or a HFD (n = 8). (D) Serum osteocalcin levels in vehicle-treated Insrfl/+ and Col1a1-Insr+/– mice and osteocalcin-treated Col1a1-Insr+/– mice fed a HFD for 8 weeks (n = 8). (E) GTT and (F) ITT of vehicle-treated Insrfl/+ and Col1a1-Insr+/– mice and OCN-treated Col1a1-Insr+/– mice fed a HFD (n = 8). (G) Serum osteocalcin levels in WT and Ocn+/– mice fed a normal diet or a HFD (n = 8). (H) Random glucose and (I) insulin levels in WT and Ocn+/– mice fed a normal diet or a HFD (n = 8). (J) GTT and (K) ITT of WT and Ocn+/– mice fed a normal diet or a HFD (n = 8). *P ≤ 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Blogged by 1
Posted by 7 X users
On 1 Facebook pages
Highlighted by 1 platforms
178 readers on Mendeley
See more details